trial

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

NCTId NCT05304767
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 280 (estimated)
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Primary completion 2026-03-19
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
280 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2022-03-07
Primary completion
2026-03-19
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Karuna Therapeutics, Inc., a Bristol Myers Squibb companyLead Sponsor

Sites

175 total
Phoenix, United StatesLittle Rock, United StatesLittle Rock, United StatesAnaheim, United StatesBellflower, United StatesCerritos, United StatesCulver City, United StatesGarden Grove, United StatesLa Habra, United StatesLafayette, United StatesLemon Grove, United StatesLos Angeles, United States

Linked catalysts

1
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive Kar — primary completion2026-03-19

Facts & assertions

4 sourced
Enrollment
280
Phase
PHASE3
Primary Completion Date
2026-03-19
Status
RECRUITING
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
company
indication
Schizophrenia
indication
Schizophrenia
indication